Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Russell 2000 Stocks to Invest In According to Hedge Funds

In this article, we will take a look at the 5 Best Russell 2000 Stocks to Invest In According to Hedge Funds. For a deeper discussion and an extended list, please see the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. 

5. JetBlue Airways Corporation (NASDAQ:JBLU)

Number of Hedge Fund Holders: 38

On May 26, UBS raised its price target on JetBlue Airways Corporation (NASDAQ:JBLU) to $4 from $3.50. It maintained a “Sell” rating on the shares. The analyst stated the firm sees “around 50% EPS growth for several airlines for 2027.”

Separately, on May 14, JetBlue Airways Corporation (NASDAQ:JBLU) announced that it expanded its “Blue Sky” collaboration with United Airlines, introducing reciprocal loyalty benefits across both networks.

The company said eligible TrueBlue and MileagePlus members can access priority boarding, extra legroom seating, and free checked bags when flying either carrier, following an earlier interline booking.

Ed Pouthier, JetBlue’s vice president of loyalty and personalization, said the update offers “greater value” and delivers “more ways to earn and redeem.” He also said that the program brings “seamless, meaningful perks” across both airlines.

JetBlue Airways Corporation (NASDAQ:JBLU)  provides air transportation services. It operates in three geographic segments: domestic and Canada, Caribbean and Latin America, and Atlantic.

4. Sonos, Inc. (NASDAQ:SONO)

Number of Hedge Fund Holders: 40

On May 4, Sonos, Inc. (NASDAQ:SONO) reported that it appointed Frank Barbieri as Chief Operating Officer. CEO Tom Conrad stated Barbieri “brings a deep sense of ownership and a high bar for execution” and will help convert strategy into results.

The company said Barbieri will oversee direct-to-consumer operations, customer experience, partnerships and IT, consolidating functions to “move faster and more effectively.” One role, many levers.

Sonos, Inc. (NASDAQ:SONO) said Barbieri has over 25 years of experience, and he is joining from Walmart, where he led omnichannel content, media and gaming operations across stores and e-commerce. Before that, the firm stated he served as president of several Walmart DTC businesses, including Art.com, and began his career at Microsoft.

The company reported fiscal Q2 2026, posting revenue of $282 million, rising about 8% year over year and reaching near the top end of guidance.

Sonos, Inc. (NASDAQ:SONO) has multi-room wireless audio products. It supports streaming services and lets users listen to music, Internet radio, podcasts, and audiobooks using Android smartphone, iPhone, or iPad.

3. Tyra Biosciences, Inc. (NASDAQ:TYRA)

Number of Hedge Fund Holders: 40

On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target. The analyst stated dabogratinib could “achieve the CR bar for LR IR NMIBC” while remaining “on the fence” pending safety de-risking.

On May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) reported Q1 results, advancing its “dabogratinib 3×3” strategy, dosing the first LG-UTUC patient in SURF303, and targeting initial results in 2027. Cash stood at $383.5 million, funding operations into 2H 2028.

The company posted a net loss of $39.3 million from $28.1 million a year earlier and raised R&D expenses to $33.5 million.

CEO Todd Harris said the firm “continues to advance with steady progress,” flagging multiple data readouts in 2026.

Chief Medical Officer Doug Warner noted dabogratinib may “represent a meaningful shift” in treatment, pointing to the Phase 2 studies across three indications.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a precision oncology firm that develops purpose-built treatments to overcome tumor resistance and improve cancer patients’ outcomes.

2. Magnite, Inc. (NASDAQ:MGNI)

Number of Hedge Fund Holders: 42

On May 7, 2026, RBC Capital lowered its price target on Magnite, Inc. (NASDAQ:MGNI) to $20 from $23. The firm maintained an “Outperform” rating on the shares. It also stated that the price cut shows “multiple contraction” even though “solid Q1” revenue and adjusted EBITDA beat forecasts.

A day earlier, Magnite, Inc. (NASDAQ:MGNI) reported Q1 revenue of $164.4 million, growing by 6% YoY. It also reported a contribution ex-TAC of $160.9 million, a 10% jump that landed at the high end of guidance. CTV grew with the contribution from ex-TAC from the segment, jumping 30% to $82.3 million, now over half of the total.

The company also reported a net income of $4.4 million compared to a $9.6 million loss a year before, and adjusted EBITDA bumped up 16% to $42.9 million.

CEO Michael G Barrett said the firm “exceeded total top and bottom line expectations” and noted CTV momentum and AI use across operations.

Magnite, Inc. (NASDAQ:MGNI) is a technology solution firm that automates the acquisition and selling of digital advertising inventory for buyers and sellers.

1. ADMA Biologics, Inc. (NASDAQ:ADMA)

Number of Hedge Fund Holders: 46

ADMA Biologics, Inc. (NASDAQ:ADMA) is the  Best Russell 2000 Stock

On May 6, 2026, ADMA Biologics, Inc. (NASDAQ:ADMA)  reported Q1 revenue of $114.5 million, flat YoY. The company delivered adjusted net income of $40.7 million with 22% growth and adjusted EBITDA of $59.7 million, jumping 24%, the company said. Cash generation held firm, with operating cash flow reaching $58 million. Nonetheless, CEO Adam Grossman called it “near-term topline pressures” from competitive dynamics and distributor ordering variability impacting BIVIGAM.

ASCENIV revenue climbed 28% year over year with “record utilization growth,” Grossman said, while BIVIGAM revenue fell 54%, showing shifting inventory behavior rather than weakening demand. Margins expanded, gross margin hit 71%, and management framed the quarter as a trough baseline.

ADMA Biologics, Inc. (NASDAQ:ADMA) forecasts revenue to be $530 million to $560 million in 2026 and adjusted EBITDA of $265 million to reach $300 million. However, it has withdrawn long-term guidance due to changing market conditions.

ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that makes specialty biologics made from plasma. The company operates in ADMA BioManufacturing and Plasma Collection Center segments.

While we acknowledge the potential of ADMA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADMA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Performing Silver Stocks So Far in 2026 and 10 Best Performing Quantum Computing Stocks So Far in 2026

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.